Table 3

Reclassification and discrimination statistics (95% CI) for 10-year risk of each secondary outcome (HF, CHD, or stroke) by circulating cardiac biomarkers among ARIC participants with diabetes

C statisticIDINRI
HF events (n = 317)
 Model 30.747 (0.719–0.774)
 Model 3 + cardiac biomarkers0.768 (0.742–0.794) (P = 0.004)0.04 (0.01–0.07) (P = 0.007)0.22 (0.06–0.30) (P = 0.027)
CHD events (n = 321)
 Model 30.692 (0.664–0.719)
 Model 3 + cardiac biomarkers0.703 (0.675–0.730) (P = 0.09)0.02 (0.01–0.05) (P < 0.001)0.14 (0.05–0.22) (P < 0.001)
Stroke events (n = 128)
 Model 30.741 (0.697–0.784)
 Model 3 + cardiac biomarkers0.749 (0.706–0.791) (P = 0.35)0.02 (0.00–0.07) (P < 0.001)0.22 (0.03–0.32) (P = 0.027)
  • Model 3 adjusted for variables in model 2 (age, sex, race, center, smoking status, log-transformed pack-years of cigarettes [packs of cigarettes smoked per day times number of years smoked], BMI, waist-to-hip ratio, mean systolic blood pressure, hypertension medication use, lipid-lowering medication use, aspirin use, education level, total-to-HDL cholesterol ratio, log-transformed triglycerides, and duration of disease) plus ECG abnormalities and conventional complications of diabetes (retinopathy, nephropathy, PAD).